The most frequent grade 3 or 4 treatment-emergent adverse events included abdominal pain (15%), lymphopenia (15%), ALT elevation (8%), AST elevation (8%), alkaline phosphatase elevation (8%), dyspnea (8%) and hypokalemia (8%) (Table S2). The gene discussed is GPT; the disease is lymphopenia.